Anna Keller, Anita Schildknecht, Yanling Xiao, M. Broek, J. Borst (2008)
Expression of costimulatory ligand CD70 on steady-state dendritic cells breaks CD8+ T cell tolerance and permits effective immunity.Immunity, 29 6
Chengwen Liu, W. Peng, Chunyu Xu, Y. Lou, Minying Zhang, J. Wargo, Jie Chen, Haiyan Li, S. Watowich, Yan Yang, Dennie Frederick, Z. Cooper, Rina Mbofung, Mayra Whittington, K. Flaherty, S. Woodman, M. Davies, L. Radvanyi, W. Overwijk, G. Lizée, P. Hwu (2012)
BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in MiceClinical Cancer Research, 19
D. Knight, S. Ngiow, Ming Li, Tiffany Parmenter, Stephen Mok, Ashley Cass, N. Haynes, K. Kinross, H. Yagita, R. Koya, T. Graeber, A. Ribas, G. McArthur, M. Smyth (2013)
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.The Journal of clinical investigation, 133 24
A. Hooijkaas, J. Gadiot, Michelle Morrow, R. Stewart, T. Schumacher, C. Blank (2012)
Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanomaOncoimmunology, 1
J. Khalili, Shujuan Liu, Tania Rodríguez-Cruz, Mayra Whittington, S. Wardell, Chengwen Liu, Minying Zhang, Z. Cooper, Dennie Frederick, Yufeng Li, Min Zhang, R. Joseph, C. Bernatchez, S. Ekmekcioglu, E. Grimm, L. Radvanyi, R. Davis, M. Davies, J. Wargo, P. Hwu, G. Lizée (2012)
Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in MelanomaClinical Cancer Research, 18
Andrea Boni, Alexandria Cogdill, P. Dang, Durga Udayakumar, C. Njauw, C. Sloss, Cristina Ferrone, K. Flaherty, D. Lawrence, D. Fisher, H. Tsao, J. Wargo (2010)
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.Cancer research, 70 13
M. Callahan, J. Wolchok, J. Allison (2010)
Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.Seminars in oncology, 37 5
Sid Kerkar, R. Goldszmid, P. Muranski, D. Chinnasamy, Zhiya Yu, R. Reger, A. Leonardi, R. Morgan, E. Wang, F. Marincola, G. Trinchieri, S. Rosenberg, N. Restifo (2011)
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.The Journal of clinical investigation, 121 12
J. Wilmott, G. Long, J. Howle, L. Haydu, Raghwa Sharma, J. Thompson, R. Kefford, P. Hersey, R. Scolyer (2011)
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic MelanomaClinical Cancer Research, 18
G. Bollag, J. Tsai, Jiazhong Zhang, Chao Zhang, P. Ibrahim, K. Nolop, P. Hirth (2012)
Vemurafenib: the first drug approved for BRAF-mutant cancerNature Reviews Drug Discovery, 11
L. Baitsch, Petra Baumgaertner, Estelle Devêvre, S. Raghav, A. Legat, L. Barba, Sébastien Wieckowski, H. Bouzourène, B. Deplancke, P. Romero, N. Rufer, D. Speiser (2011)
Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients.The Journal of clinical investigation, 121 6
S. Shiao, Ganesan Ap, Ganesan Ap, H. Rugo, L. Coussens (2011)
Immune microenvironments in solid tumors: new targets for therapy.Genes & development, 25 24
Katherine Deusen, Rohan Rajapakse, T. Bullock (2010)
CD70 expression by dendritic cells plays a critical role in the immunogenicity of CD40‐independent, CD4+ T cell‐dependent, licensed CD8+ T cell responsesJournal of Leukocyte Biology, 87
D. Dankort, D. Curley, Robert Cartlidge, Betsy Nelson, A. Karnezis, W. Damsky, M. You, R. DePinho, M. McMahon, M. Bosenberg (2009)
BRafV600E cooperates with Pten silencing to elicit metastatic melanomaNature genetics, 41
H. Braumüller, T. Wieder, E. Brenner, Sonja Assmann, M. Hahn, M. Alkhaled, K. Schilbach, F. Essmann, M. Kneilling, C. Griessinger, Felicia Ranta, S. Ullrich, R. Mocikat, Kilian Braungart, T. Mehra, B. Fehrenbacher, Julia Berdel, H. Niessner, F. Meier, M. Broek, H. Häring, R. Handgretinger, L. Quintanilla‐Martinez, F. Fend, M. Pesic, J. Bauer, L. Zender, M. Schaller, K. Schulze-Osthoff, M. Röcken (2013)
T-helper-1-cell cytokines drive cancer into senescenceNature, 494
K. Wiggins, Valerie Davis, Dhiral Phadke, Ruchir Shah, T. Archer (2012)
Abstract 3928: Inhibition of the ubiquitin proteasome system differentially regulates glucocorticoid receptor-mediated transcriptional processesCancer Research, 72
S. Jang, M. Atkins (2013)
Which drug, and when, for patients with BRAF-mutant melanoma?The Lancet. Oncology, 14 2
D. Mosser, J. Edwards (2008)
Exploring the full spectrum of macrophage activationNature Reviews Immunology, 8
of Potential Conflicts of Interest No potential conflicts of interest were disclosed
I. Angulo, J. Rullas, J. Campillo, E. Obregón, A. Heath, M. Howard, M. Muñoz-Fernández, J. Subiza (2000)
Early myeloid cells are high producers of nitric oxide upon CD40 plus IFN-gamma stimulation through a mechanism dependent on endogenous TNF-alpha and IL-1alpha.European journal of immunology, 30 5
J. Sosman, Kevin Kim, L. Schuchter, R. Gonzalez, A. Pavlick, J. Weber, G. McArthur, Thomas Hutson, S. Moschos, K. Flaherty, P. Hersey, R. Kefford, D. Lawrence, I. Puzanov, K. Lewis, R. Amaravadi, B. Chmielowski, H. Lawrence, Y. Shyr, Fei Ye, Jiang Li, K. Nolop, Richard Lee, A. Joe, A. Ribas (2012)
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.The New England journal of medicine, 366 8
Wen-Chin Yang, Ge Ma, Shu-Hsia Chen, P. Pan (2013)
Polarization and reprogramming of myeloid-derived suppressor cells.Journal of molecular cell biology, 5 3
J. Wolchok, H. Kluger, M. Callahan, M. Postow, N. Rizvi, A. Lesokhin, N. Segal, C. Ariyan, R. Gordon, Kathleen Reed, M. Burke, A. Caldwell, S. Kronenberg, B. Agunwamba, Xiaoling Zhang, I. Lowy, H. Inzunza, W. Feely, C. Horak, Q. Hong, A. Korman, J. Wigginton, A. Gupta, M. Sznol (2013)
Nivolumab plus ipilimumab in advanced melanoma.The New England journal of medicine, 369 2
(2014)
BRAF Inhibitor-Induced Antitumor Immunity
R. Koya, Stephen Mok, N. Otte, Kevin Blacketor, Begonya Comin-Anduix, P. Tumeh, Aspram Minasyan, N. Graham, T. Graeber, T. Chodon, A. Ribas (2012)
BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy.Cancer research, 72 16
Xiaofeng Jiang, Jun Zhou, A. Giobbie-Hurder, J. Wargo, Stephen Hodi (2012)
The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K InhibitionClinical Cancer Research, 19
A. Hooijkaas, J. Gadiot, M. Valk, W. Mooi, C. Blank (2012)
Targeting BRAFV600E in an inducible murine model of melanoma.The American journal of pathology, 181 3
R. Vonderheide, M. Glennie (2013)
Agonistic CD40 Antibodies and Cancer TherapyClinical Cancer Research, 19
Ying Xie, A. Akpinarli, C. Maris, Edward Hipkiss, M. Lane, Eun-Kyung Kwon, P. Muranski, N. Restifo, P. Antony (2010)
Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanomaThe Journal of Experimental Medicine, 207
Arnaldur Hall, K. Meyle, M. Lange, M. Klíma, May Sanderhoff, C. Dahl, C. Abildgaard, K. Thorup, S. Moghimi, P. Jensen, J. Bartek, P. Guldberg, C. Christensen (2013)
Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the V600EBRAF oncogeneOncotarget, 4
S. Swain, K. McKinstry, T. Strutt (2012)
Expanding roles for CD4+ T cells in immunity to virusesNature Reviews. Immunology, 12
E. Higham, K. Wittrup, Jianzhu Chen (2010)
Activation of Tolerogenic Dendritic Cells in the Tumor Draining Lymph Nodes by CD8+ T Cells Engineered to Express CD40 LigandThe Journal of Immunology, 184
Sid Kerkar, N. Restifo (2012)
Cellular constituents of immune escape within the tumor microenvironment.Cancer research, 72 13
Drew Roberts, N. Franklin, Lara Kingeter, H. Yagita, A. Tutt, M. Glennie, T. Bullock (2010)
Control of Established Melanoma by CD27 Stimulation Is Associated With Enhanced Effector Function and Persistence, and Reduced PD-1 Expression of Tumor Infiltrating CD8+ T CellsJournal of Immunotherapy, 33
(2013)
Clinical cancer research : an official journal of the American Association for Cancer Research
R. Kornbluth, K. Kee, D. Richman (1998)
CD40 ligand (CD154) stimulation of macrophages to produce HIV-1-suppressive beta-chemokines.Proceedings of the National Academy of Sciences of the United States of America, 95 9
M. Kalos, C. June (2013)
Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology.Immunity, 39 1
I. Angulo, J. Rullas, J. Campillo, E. Obregón, A. Heath, M. Howard, M. Muñoz-Fernández, J. Subiza (2000)
Early myeloid cells are high producers of nitric oxide upon CD40 plus IFN‐γ stimulation through a mechanism dependent on endogenous TNF‐α and IL‐1αEuropean Journal of Immunology, 30
Xiaofeng Jiang, Wenyu Sun, Dawei Guo, Zheming Cui, Lei Zhu, Lin Lin, Yu-fu Tang, Xue-fan Wang, Jian Liang (2011)
Cardiac allograft acceptance induced by blockade of CD40-CD40L costimulation is dependent on CD4+CD25+ regulatory T cells.Surgery, 149 3
A. Baudy, Taner Dogan, Judith Flores-Mercado, K. Hoeflich, F. Su, N. Bruggen, Simon-Peter Williams (2012)
FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973EJNMMI Research, 2
K. Rakhra, P. Bachireddy, Tahera Zabuawala, R. Zeiser, Liwen Xu, Andrew Kopelman, A. Fan, Qiwei Yang, L. Braunstein, Erika Crosby, S. Ryeom, D. Felsher (2010)
CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation.Cancer cell, 18 5
Dennie Frederick, A. Piris, Alexandria Cogdill, Z. Cooper, C. Lezcano, Cristina Ferrone, D. Mitra, Andrea Boni, Lindsay Newton, Chengwen Liu, W. Peng, R. Sullivan, D. Lawrence, F. Hodi, W. Overwijk, G. Lizée, G. Murphy, P. Hwu, K. Flaherty, D. Fisher, J. Wargo (2013)
BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic MelanomaClinical Cancer Research, 19
D. Propper, D. Chao, J. Braybrooke, P. Bahl, P. Thavasu, F. Balkwill, H. Turley, N. Dobbs, K. Gatter, D. Talbot, A. Harris, T. Ganesan (2003)
Low-Dose IFN-γ Induces Tumor MHC Expression in Metastatic Malignant MelanomaClinical Cancer Research, 9
Long Zhang, Xiufen Chen, Xiao Liu, Douglas Kline, R. Teague, T. Gajewski, J. Kline (2013)
CD40 ligation reverses T cell tolerance in acute myeloid leukemia.The Journal of clinical investigation, 123 5
G. Beatty, E. Chiorean, Matthew Fishman, B. Saboury, U. Teitelbaum, Weijing Sun, R. Huhn, Wenru Song, Dongguang Li, L. Sharp, D. Torigian, P. O'dwyer, R. Vonderheide (2011)
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and HumansScience, 331
D. Propper, D. Chao, J. Braybrooke, P. Bahl, P. Thavasu, F. Balkwill, H. Turley, N. Dobbs, K. Gatter, D. Talbot, A. Harris, T. Ganesan (2003)
Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research, 9 1
R. Haq, Jonathan Shoag, Pedro Andreu-Pérez, S. Yokoyama, Hannah Edelman, G. Rowe, Dennie Frederick, Aeron Hurley, Abhinav Nellore, A. Kung, J. Wargo, Jun Song, D. Fisher, Z. Arany, H. Widlund (2013)
Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF.Cancer cell, 23 3
P. Murray, T. Wynn (2011)
Protective and pathogenic functions of macrophage subsetsNature Reviews Immunology, 11
(2014)
www.aacrjournals.org Cancer Res
N. Hunder, H. Wallen, Jianhong Cao, Deborah Hendricks, J. Reilly, Rebecca Rodmyre, A. Jungbluth, S. Gnjatic, John Thompson, C. Yee (2008)
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.The New England journal of medicine, 358 25
(2014)
American Association for Cancer cancerres.aacrjournals.org Downloaded from
E. Wherry, S. Ha, S. Kaech, W. Haining, S. Sarkar, V. Kalia, Shruti Subramaniam, J. Blattman, D. Barber, R. Ahmed (2007)
Molecular signature of CD8+ T cell exhaustion during chronic viral infection.Immunity, 27 4
S. Bak, Mike Barnkob, A. Bai, E. Higham, K. Wittrup, Jianzhu Chen (2012)
Differential Requirement for CD70 and CD80/CD86 in Dendritic Cell-Mediated Activation of Tumor-Tolerized CD8 T CellsThe Journal of Immunology, 189
K. Flaherty, J. Infante, A. Daud, R. Gonzalez, R. Kefford, J. Sosman, O. Hamid, L. Schuchter, J. Cebon, N. Ibrahim, R. Kudchadkar, H. Burris, G. Falchook, A. Algazi, K. Lewis, G. Long, I. Puzanov, P. Lebowitz, A. Singh, S. Little, P. Sun, A. Allred, D. Ouellet, Kevin Kim, K. Patel, J. Weber (2012)
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.The New England journal of medicine, 367 18
W. Damsky, D. Curley, M. Santhanakrishnan, L. Rosenbaum, J. Platt, B. Rothberg, M. Taketo, D. Dankort, D. Rimm, M. McMahon, M. Bosenberg (2011)
β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas.Cancer cell, 20 6
L. Baitsch, Silvia Fuertes-Marraco, A. Legat, C. Meyer, D. Speiser (2012)
The three main stumbling blocks for anticancer T cells.Trends in immunology, 33 7
M. Allalunis-Turner, D. Siemann (1986)
Recovery of cell subpopulations from human tumour xenografts following dissociation with different enzymes.British Journal of Cancer, 54
Nancie MacIver, Ryan Michalek, J. Rathmell (2013)
Metabolic regulation of T lymphocytes.Annual review of immunology, 31
J. Liu, L. Hesson, A. Meagher, M. Bourke, N. Hawkins, K. Rand, P. Molloy, J. Pimanda, R. Ward (2012)
Abstract 3125: Relative distribution of folate species is associated with global DNA methylation in human colorectal mucosaCancer Research, 72
Cancer Research – Unpaywall
Published: Apr 16, 2014
Access the full text.
Sign up today, get DeepDyve free for 14 days.